抗疟药物耐药性：将恶性疟原虫生物学与临床联系起来
Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic.
作者信息
Blasco Benjamin, Leroy Didier, Fidock David A
机构信息
Medicines for Malaria Venture, Geneva, Switzerland.
Department of Microbiology and Immunology, Columbia University Medical Center, New York, New York, USA.
出版信息
Nat Med. 2017 Aug 4;23(8):917-928. doi: 10.1038/nm.4381.
Abstract
The global adoption of artemisinin-based combination therapies (ACTs) in the early 2000s heralded a new era in effectively treating drug-resistant Plasmodium falciparum malaria. However, several Southeast Asian countries have now reported the emergence of parasites that have decreased susceptibility to artemisinin (ART) derivatives and ACT partner drugs, resulting in increasing rates of treatment failures. Here we review recent advances in understanding how antimalarials act and how resistance develops, and discuss new strategies for effectively combatting resistance, optimizing treatment and advancing the global campaign to eliminate malaria.
摘要
21世纪初基于青蒿素的联合疗法（ACTs）在全球范围内的采用开创了有效治疗耐药恶性疟原虫疟疾的新纪元。然而，现在几个东南亚国家报告称出现了对青蒿素（ART）衍生物和ACT联合用药敏感性降低的寄生虫，导致治疗失败率不断上升。在此，我们回顾了在理解抗疟药物的作用方式以及耐药性如何产生方面的最新进展，并讨论了有效对抗耐药性、优化治疗以及推进全球疟疾消除运动的新策略。
相似文献
1
Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic.
Nat Med. 2017 Aug 4;23(8):917-928. doi: 10.1038/nm.4381.
2
How genomics is contributing to the fight against artemisinin-resistant malaria parasites.
Acta Trop. 2015 Aug;148:1-7. doi: 10.1016/j.actatropica.2015.04.007. Epub 2015 Apr 21.
3
Plasmodium falciparum resistance to artemisinin-based combination therapies: A sword of Damocles in the path toward malaria elimination.
Parasite. 2018;25:24. doi: 10.1051/parasite/2018021. Epub 2018 Apr 20.
4
Induction of Multidrug Tolerance in Plasmodium falciparum by Extended Artemisinin Pressure.
Emerg Infect Dis. 2015 Oct;21(10):1733-41. doi: 10.3201/eid2110.150682.
5
Artemisinin-Resistant Plasmodium falciparum Malaria.
Microbiol Spectr. 2016 Jun;4(3). doi: 10.1128/microbiolspec.EI10-0013-2016.
6
Triple Artemisinin-Based Combination Therapies for Malaria - A New Paradigm?
Trends Parasitol. 2021 Jan;37(1):15-24. doi: 10.1016/j.pt.2020.09.011. Epub 2020 Oct 12.
7
Artemisinin derivatives and malaria: useful, in combination with other antimalarials.
Prescrire Int. 2008 Aug;17(96):162-8.
8
Antimalarial drug resistance in Africa: the calm before the storm?
Lancet Infect Dis. 2019 Oct;19(10):e338-e351. doi: 10.1016/S1473-3099(19)30261-0. Epub 2019 Jul 30.
9
Artemisinin Action and Resistance in Plasmodium falciparum.
Trends Parasitol. 2016 Sep;32(9):682-696. doi: 10.1016/j.pt.2016.05.010. Epub 2016 Jun 9.
10
Artemisinin resistance in Plasmodium falciparum: what is it really?
Trends Parasitol. 2013 Jul;29(7):318-20. doi: 10.1016/j.pt.2013.05.002. Epub 2013 Jun 11.
引用本文的文献
1
Novel Inhibitors of Phosphatidylinositol 4-kinase IIIβ with Low Propensity for Resistance: Life Cycle Stage Activity and Efficacy in a Humanized Mouse Malaria Infection Model.
J Med Chem. 2025 Aug 28;68(16):17736-17751. doi: 10.1021/acs.jmedchem.5c01417. Epub 2025 Aug 14.
2
Antimalarial activity of root extract of Tephrosia villosa L. Pers. (Fabaceae) on Plasmodium berghei-infected mice.
Sci Rep. 2025 Jul 25;15(1):27162. doi: 10.1038/s41598-025-11137-0.
3
Direct long-read visualization reveals hidden variation in GCH1 gene copy number and precise expansion steps.
BMC Genomics. 2025 Jul 17;26(1):671. doi: 10.1186/s12864-025-11859-5.
4
Comprehensive genomic study of Plasmodium falciparum in Sierra leone: genetic variation and resistance patterns.
BMC Genomics. 2025 Jul 1;26(1):584. doi: 10.1186/s12864-025-11771-y.
5
Malaria: past, present, and future.
Signal Transduct Target Ther. 2025 Jun 17;10(1):188. doi: 10.1038/s41392-025-02246-3.
6
A comprehensive review of cerebral malaria.
J Parasit Dis. 2025 Jun;49(2):257-272. doi: 10.1007/s12639-024-01758-z. Epub 2024 Nov 15.
7
Emerging Plasmodium falciparum K13 gene mutation to artemisinin-based combination therapies and partner drugs among malaria-infected population in sub-Saharan Africa.
Parasites Hosts Dis. 2025 May;63(2):109-122. doi: 10.3347/PHD.24053. Epub 2025 May 26.
8
Repurposing antimalarials: pyrimethamine exhibits superior in vitro activity to metronidazole against Gardnerella while sparing Lactobacillus.
J Antimicrob Chemother. 2025 Jul 1;80(7):1972-1979. doi: 10.1093/jac/dkaf157.
9
The fast-evolving FIKK kinase family of Plasmodium falciparum can be inhibited by a single compound.
Nat Microbiol. 2025 May 19. doi: 10.1038/s41564-025-02017-4.
10
The ATM Kinase Inhibitor AZD0156 Is a Potent Inhibitor of Plasmodium Phosphatidylinositol 4-Kinase (PI4Kβ) and Is an Attractive Candidate for Medicinal Chemistry Optimization Against Malaria.
Angew Chem Int Ed Engl. 2025 Jul 7;64(28):e202425206. doi: 10.1002/anie.202425206. Epub 2025 May 15.
本文引用的文献
1
Protein Degradation Systems as Antimalarial Therapeutic Targets.
Trends Parasitol. 2017 Sep;33(9):731-743. doi: 10.1016/j.pt.2017.05.009. Epub 2017 Jul 5.
2
A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance.
Nat Commun. 2017 May 24;8:15159. doi: 10.1038/ncomms15159.
3
A Variant PfCRT Isoform Can Contribute to Resistance to the First-Line Partner Drug Piperaquine.
mBio. 2017 May 9;8(3):e00303-17. doi: 10.1128/mBio.00303-17.
4
Oxidative stress in malaria and artemisinin combination therapy: Pros and Cons.
FEBS J. 2017 Aug;284(16):2579-2591. doi: 10.1111/febs.14097. Epub 2017 May 25.
5
Antimalarial efficacy of MMV390048, an inhibitor of phosphatidylinositol 4-kinase.
Sci Transl Med. 2017 Apr 26;9(387). doi: 10.1126/scitranslmed.aad9735.
6
K13 Mutations Differentially Impact Ozonide Susceptibility and Parasite Fitness .
mBio. 2017 Apr 11;8(2):e00172-17. doi: 10.1128/mBio.00172-17.
7
Association of glucose-6-phosphate dehydrogenase deficiency and malaria: a systematic review and meta-analysis.
Sci Rep. 2017 Apr 6;7:45963. doi: 10.1038/srep45963.
8
Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study.
Lancet Infect Dis. 2017 Jun;17(6):626-635. doi: 10.1016/S1473-3099(17)30171-8. Epub 2017 Mar 28.
9
Targeting the Parasite to Suppress Malaria Transmission.
Adv Parasitol. 2017;97:147-185. doi: 10.1016/bs.apar.2016.09.004. Epub 2016 Nov 12.
10
Mefloquine targets the Plasmodium falciparum 80S ribosome to inhibit protein synthesis.
Nat Microbiol. 2017 Mar 13;2:17031. doi: 10.1038/nmicrobiol.2017.31.
Zotero 插件